Susquehanna International Group, LLP Tyme Technologies, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$0.23 - $0.35 $11,339 - $17,255	-49,300 Reduced 29.72%	116,600 $33,000
Q1 2022 May 16, 2022	BUY	$0.28 - $0.68 $7,728 - $18,768	27,600 Added 19.96%	165,900 $58,000
Q4 2021 Feb 14, 2022	BUY	$0.6 - $1.04 $24,180 - $41,912	40,300 Added 41.12%	138,300 $83,000
Q3 2021 Nov 15, 2021	SELL	$0.99 - $1.38 $108,306 - $150,972	-109,400 Reduced 52.75%	98,000 $101,000
Q2 2021 Aug 11, 2021	SELL	$1.14 - $1.87 $295,944 - $485,452	-259,600 Reduced 55.59%	207,400 $261,000
Q1 2021 May 17, 2021	BUY	$1.34 - $3.53 $572,582 - $1.51 Million	427,300 Added 1076.32%	467,000 $831,000
Q3 2019 Nov 14, 2019	BUY	$0.97 - $1.77 $28,227 - $51,507	29,100 Added 274.53%	39,700 $47,000
Q2 2019 Aug 14, 2019	SELL	$0.96 - $1.89 $10,944 - $21,546	-11,400 Reduced 51.82%	10,600 $13,000
Q1 2019 May 15, 2019	BUY	$1.76 - $3.73 $38,720 - $82,060	22,000 New	22,000 $39,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.